Back
47· Steady
Technology1h 26m ago
An expert roundtable discussed the clinical challenges of managing patients with co-occurring ESR1 and PIK3CA mutations in ER+ metastatic breast cancer.
N/A
Who
Drs. Seth Wander, Virginia Kaklamani, Monica Fornier, and Neil Iyengar
What
An expert roundtable discussed the clinical challenges of managing patients with co-occurring ESR1 and PIK3CA mutations in ER+ metastatic breast cancer.
When
Mon, 15 Jun 2026 19:48:40 GMT · 1h 26m ago
Where
N/A ·
Why
The discussion aimed to address how to prioritize targeted therapies and balance efficacy with toxicity for patients with these specific co-mutations.
The Frontline Impact
How this affects you
The medical field is seeking better treatment strategies and personalized care for patients with ER+ metastatic breast cancer, particularly those with ESR1 and PIK3CA co-mutations, to improve outcomes and manage treatment-related toxicities. Advances in this area could significantly enhance patient quality of life and survival rates, reflecting a broader trend towards more precise oncology treatments.
Story chain
2 events in this thread- Currently Reading1h 26m agoAn expert roundtable discussed the clinical challenges of managing patients with co-occurring ESR1 and PIK3CA mutations in ER+ metastatic breast cancer.
- Technology2h 14m agoMedical professionals are discussing the clinical differentiation, efficacy, and safety of oral SERDs (Selective Estrogen Receptor Degraders) for ESR1-mutated ER-positive metastatic breast cancer, examining their use as monotherapy versus combination therapy.Open article
Verified Sources & Citations
- HIGHDocwire Newshttps://www.docwirenews.com/post/oral-serds-in-esr1-mutated-disease-clinical-differentiation-and-use
- HIGHDocwire Newshttps://www.docwirenews.com/post/managing-esr1-and-pik3ca-co-mutations-in-er-metastatic-breast-cancer
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.